NeuroBo Pharmaceuticals I... (NRBO)
NeuroBo Pharmaceuticals Statistics
Share Statistics
NeuroBo Pharmaceuticals has 8.62M shares outstanding. The number of shares has increased by 74.93% in one year.
| Shares Outstanding | 8.62M |
| Shares Change (YoY) | 74.93% |
| Shares Change (QoQ) | 49.7% |
| Owned by Institutions (%) | 4.59% |
| Shares Floating | 2.1M |
| Failed to Deliver (FTD) Shares | 2.69K |
| FTD / Avg. Volume | 5.99% |
Short Selling Information
The latest short interest is 19.2K, so undefined% of the outstanding shares have been sold short.
| Short Interest | 19.2K |
| Short % of Shares Out | undefined% |
| Short % of Float | 0.64% |
| Short Ratio (days to cover) | 0.38 |
Valuation Ratios
The PE ratio is undefined and the forward PE ratio is -1.51. NeuroBo Pharmaceuticals's PEG ratio is undefined.
| PE Ratio | undefined |
| Forward PE | -1.51 |
| PS Ratio | 0 |
| Forward PS | 2904.8 |
| PB Ratio | 1.12 |
| P/FCF Ratio | undefined |
| PEG Ratio | undefined |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for NeuroBo Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.78, with a Debt / Equity ratio of undefined.
| Current Ratio | 3.78 |
| Quick Ratio | 3.78 |
| Debt / Equity | undefined |
| Debt / EBITDA | - |
| Debt / FCF | - |
| Interest Coverage | undefined |
Financial Efficiency
Return on Equity is -0.75% and Return on Invested Capital is -94.07%.
| Return on Equity | -0.75% |
| Return on Assets | -0.55% |
| Return on Invested Capital | -94.07% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.56M |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -39.8% in the last 52 weeks. The beta is -0.28, so NeuroBo Pharmaceuticals's price volatility has been lower than the market average.
| Beta | -0.28 |
| 52-Week Price Change | -39.8% |
| 50-Day Moving Average | 2.73 |
| 200-Day Moving Average | 3.81 |
| Relative Strength Index (RSI) | 40.85 |
| Average Volume (20 Days) | 45K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -15.89M |
| Net Income | -12.47M |
| EBITDA | -15.88M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.46 |
Balance Sheet
The company has 22.43M in cash and 203K in debt, giving a net cash position of 22.23M.
| Cash & Cash Equivalents | 22.43M |
| Total Debt | 203K |
| Net Cash | 22.23M |
| Retained Earnings | -108.27M |
| Total Assets | 22.15M |
| Working Capital | 12.82M |
Cash Flow
In the last 12 months, operating cash flow was -10.8M and capital expenditures -50K, giving a free cash flow of -10.85M.
| Operating Cash Flow | -10.8M |
| Capital Expenditures | -50K |
| Free Cash Flow | -10.85M |
| FCF Per Share | -2.14 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NRBO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -104.24% |
| FCF Yield | -53.35% |
Analyst Forecast
The average price target for NRBO is $10, which is 323.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 323.7% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Dec 21, 2023. It was a backward split with a ratio of 1:8.
| Last Split Date | Dec 21, 2023 |
| Split Type | backward |
| Split Ratio | 1:8 |
Scores
| Altman Z-Score | -10.06 |
| Piotroski F-Score | 2 |